NEW YORK (GenomeWeb News) – Roche's 454 Life Sciences said this week that its Genome Sequencer FLX has been installed at the University of Barcelona in Spain. The university's Genomics Unit of the Scientific and Technical Services will use the platform to study aquaculture and DNA alterations related to human diseases.
Waters said that the National Cancer Institute's Center for Cancer Research has purchased an Acquity UPLC/Synapt HDMS system and an Acquity UPLC/Xevo TQ MS system for use in its metabolomics research programs.
Beckman Coulter's Agencourt Bioscience said that it has added an Illumina Genome Analyzer II to its suite of next-generation sequencing instruments. The firm also has next-generation sequencing systems from 454 Life Sciences and Applied Biosystems, which it uses in its genomics services offerings.
A paper published in the Journal of Clinical Oncology this week detailed a validation study of Pathwork Diagnostics' Tissue of Origin test. The study included 547 specimens and showed that the test "has significant potential to reduce diagnostic uncertainty for poorly differentiated, undifferentiated, or metastatic tumors," the firm said in a statement. The US Food and Drug Administration cleared the microarray test in July.
The Ontario Cancer Biomarker Network this week said that it is using GenoLogics' Proteus system for integrating proteomics data across multiple labs.
Tecan said that Quanterix is using the firm's Freedom EVO liquid handling workstation in developing its Single Molecule Array technology.
CombiMatrix said that the Agency for Health Protection and Promotion in Ontario, Canada, has verified the function of the firm's influenza detection system during the 2007-2008 flu season. The company said that study results published in the March 25 issue of the Virology Journal showed 95.2 percent sensitivity and 100 percent selectivity for the system.